GGrantIndex
← Leaderboards

Lawrence R Toll

Sri International

Google Scholar ↗PubMed ↗ORCID ↗
$15,551,699
Attributed
$22,883,239
Total exposure
14
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.7M · FY2006–25
$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$22,883,239 · 14

By mechanism

R01$11,567,326 · 4
U01$8,683,509 · 1
R21$1,142,775 · 3
R41$1,022,410 · 4
R43$287,219 · 1
R13$180,000 · 1

Top collaborators

Others in their field

Top investigators on “Receptor”

Research focus

ReceptorPharmaceutical PreparationsBrainAnalgesicsAgonistOpioidOpioid ReceptorLigandsGrantPropertyDesignFamilyPainIn VivoIn VitroDrug AbuseChronic PainResponseMediatingAffinityReceptor ActivationRewardsAcuteAttenuated

Grant awards (47)

HNK analog identification and characterization as an approach to non-opioid analgesics$290,784
R41 · FY2025 · NS · contact PI
Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder$3,623,079
U01 · FY2024 · DA · contact PI
51st to 55th ANNUAL INTERNATIONAL NARCOTICS RESEARCHCONFERENCES$36,000
R13 · FY2024 · DA · contact PI
Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder$2,380,269
U01 · FY2023 · DA · contact PI
Identification of Mixed NOP/mu partial agonists as lead compounds for treatment of methamphetamine use disorder$319,983
R41 · FY2023 · DA
51st to 55th ANNUAL INTERNATIONAL NARCOTICS RESEARCHCONFERENCES$36,000
R13 · FY2023 · DA · contact PI
Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder$2,680,161
U01 · FY2022 · DA · contact PI
51st to 55th ANNUAL INTERNATIONAL NARCOTICS RESEARCHCONFERENCES$36,000
R13 · FY2022 · DA · contact PI
MIXED NOP/MU COMPOUNDS AND THE INVOLVEMENT OF THEIR RECEPTORS IN ANALGESIA$452,403
R01 · FY2021 · DA · contact PI
Cell Specific Identification of IL-1R Actions in Acute and Chronic Pain$411,125
R21 · FY2021 · NS · contact PI
51st to 55th ANNUAL INTERNATIONAL NARCOTICS RESEARCHCONFERENCES$36,000
R13 · FY2021 · DA · contact PI
MIXED NOP/MU COMPOUNDS AND THE INVOLVEMENT OF THEIR RECEPTORS IN ANALGESIA$452,881
R01 · FY2020 · DA · contact PI
51st to 55th ANNUAL INTERNATIONAL NARCOTICS RESEARCHCONFERENCES$36,000
R13 · FY2020 · DA · contact PI
MIXED NOP/MU COMPOUNDS AND THE INVOLVEMENT OF THEIR RECEPTORS IN ANALGESIA$453,345
R01 · FY2019 · DA · contact PI
NPQ/Spexin the Endogenous Ligand for the Galanin Receptor 3$606,803
R01 · FY2018 · DA · contact PI
MIXED NOP/MU COMPOUNDS AND THE INVOLVEMENT OF THEIR RECEPTORS IN ANALGESIA$518,916
R01 · FY2018 · DA · contact PI
The Kappa Partial Agonist PPL-103 as a Potential Cocaine Abuse Pharmacotherapy$186,687
R41 · FY2018 · DA · contact PI
NPQ/Spexin the Endogenous Ligand for the Galanin Receptor 3$714,012
R01 · FY2017 · DA
Mixed NOP/mu Compounds and the Involvement of Their Receptors in Analgesia$652,346
R01 · FY2017 · DA · contact PI
NPQ/Spexin the Endogenous Ligand for the Galanin Receptor 3$742,361
R01 · FY2016 · DA · contact PI
Discovery of alpha4beta2 Nicotinic Receptor Antagonists as Alcohol Abuse Medications$224,956
R41 · FY2016 · AA · contact PI
Mixed NOP/mu compounds and the involvement of their receptors in analgesia.$458,010
R01 · FY2015 · DA · contact PI
Mixed NOP/mu compounds and the involvement of their receptors in analgesia.$516,146
R01 · FY2014 · DA · contact PI
Mixed NOP/mu Compounds and the Involvement of their Receptors in Analgesia$41,181
R01 · FY2014 · DA · contact PI
Mixed NOP/mu compounds and the involvement of their receptors in analgesia.$334,030
R01 · FY2013 · DA · contact PI
Mixed NOP/mu compounds and the involvement of their receptors in analgesia.$357,460
R01 · FY2012 · DA · contact PI
Mixed NOP/mu compounds and the involvement of their receptors in analgesia.$400,849
R01 · FY2011 · DA · contact PI
Mixed NOP/mu compounds and the involvement of their receptors in analgesia$426,651
R01 · FY2010 · DA · contact PI
Subtype-Selective Nicotinic Receptor Ligands as Smoking Cessation Pharmacotherapy$389,916
R01 · FY2010 · DA · contact PI
Nasocerebral administration of peptides for temporomandibular joint pain$61,167
R43 · FY2010 · DA · contact PI
Mixed NOP/mu compounds and the involvement of their receptors in analgesia$12,328
R01 · FY2010 · DA · contact PI
Mixed NOP/mu compounds and the involvement of their receptors in analgesia$425,931
R01 · FY2009 · DA · contact PI
Subtype-Selective Nicotinic Receptor Ligands as Smoking Cessation Pharmacotherapy$393,849
R01 · FY2009 · DA · contact PI
Mixed NOP/mu compounds and the involvement of their receptors in analgesia$97,296
R01 · FY2009 · DA · contact PI
Subtype-Selective Nicotinic Receptor Ligands as Smoking Cessation Pharmacotherapy$393,870
R01 · FY2008 · DA · contact PI
Mixed NOP/mu compounds and the involvement of their receptors in analgesia$389,198
R01 · FY2008 · DA · contact PI
Nasocerebral administration of peptides for temporomandibular joint pain$226,052
R43 · FY2008 · DA · contact PI
Subtype-Selective Nicotinic Receptor Ligands as Smoking Cessation Pharmacotherapy$401,901
R01 · FY2007 · DA · contact PI
Mixed NOP/mu compounds and the involvement of their receptors in analgesia$393,995
R01 · FY2007 · DA · contact PI
Subtype-Selective Nicotinic Receptor Ligands as Smoking Cessation Pharmacotherapy$412,278
R01 · FY2006 · DA · contact PI
COMPUTATIONAL APPROACH TO NEUROPEPTIDES AND DRUG ABUSE$194,985
R21 · FY2004 · DA
COMPUTATIONAL APPROACH TO NEUROPEPTIDES AND DRUG ABUSE$195,376
R21 · FY2003 · DA
BIOCHEMICAL STUDIES OF OPIATE EFFICACIES$393,043
R01 · FY2002 · DA
BIOCHEMICAL STUDIES OF OPIATE EFFECACIES$392,349
R01 · FY2001 · DA
IDENTIFYING OPIOID TOLERANCE &DEPENDENCE-RELATED GENES$172,037
R21 · FY2001 · DA
BIOCHEMICAL STUDIES OF OPIATE EFFECACIES$343,978
R01 · FY2000 · DA
IDENTIFYING OPIOID TOLERANCE &DEPENDENCE-RELATED GENES$169,252
R21 · FY2000 · DA